Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response

Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft-tissue sarcomas refractory to standard therapies. Inactivation of NF1 and subsequent upregulation of RAS/RAF/MEK/ERK signaling exist in the majority of MPNSTs. However, the lack of preclinical assessment of MEK inhibitors in MPNSTs hind...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yihui Gu, Wei Wang, Yuehua Li, Haibo Li, Zizhen Guo, Chengjiang Wei, Manmei Long, Manhon Chung, Rehanguli Aimaier, Qingfeng Li, Zhichao Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-07-01
coleção:	Frontiers in Oncology
Assuntos:	neurofibromatosis type 1 malignant peripheral nerve sheath tumors (MPNST) mek inhibitor trametinib target therapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.903177/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!